Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q4 2017 · 10-K
Revenue$6.35M$6.35M+168.7% vs Q4 2016 Net Income-$11.83M-$11.83MN/M vs Q4 2016 EPS Diluted-$0.40-$0.40N/M vs Q4 2016 Operating Income-$12,347,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,995,000N/M Margins · derivedOperating margin-194.6%+391.5 pt vs Q4 2016
Net margin-186.4%+434.9 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 14, 2018 · 73 d after period end